BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 11, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 2, 2004
View Archived Issues
Money Raised Year To Date
Read More
Stock Winners and Losers For The Week
Read More
Underwriters' Performance on All Public Offerings Jan. 1 - Dec. 31, 2003: Full Credit to All Underwriters, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on All Public Offerings Jan. 1 - Dec. 31, 2003: Full Credit to All Underwriters, Ranked by After-Market Performance*#
Read More
Underwriters' Performance on All Public Offerings from Jan. 1, 2003, to Dec. 31, 2003: Full Credit to Lead Underwriters, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on All Public Offerings from Jan. 1, 2003, to Dec. 31, 2003: Full Credit to Lead Underwriters, Ranked by After-Market Performance#
Read More
Underwriters' Performance on IPOS from Jan. 1, 2003, to Dec. 31, 2003: Full Credit to Lead Underwriter, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on IPOS from Jan. 1, 2003, to Dec. 31, 2003: Full Credit to Lead Underwriter, Ranked by After-Market Performance#
Read More
Underwriters' Performance on IPOS from Jan. 1, 2003, to Dec. 31, 2003: Full Credit to All Underwriters, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on IPOS from Jan. 1, 2003, to Dec. 31, 2003: Full Credit to All Underwriters, Ranked by After-Market Performance#
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More
In U.S., Overseas, Companies Eyeing Biogenerics Windfall
Read More
